We currently represent several high quality biotech companies in multi-track licensing and M&A engagements, including:

• A Phase III GI orphan drug opportunity, with positive EMA Advice Letter
• A company with a novel monoclonal antibody targeting FGF2
• A company with a novel biologic for the treatment of IgA nephropathy, an orphan renal disorder
• An oncology company with a novel, proprietary, targeted compound for solid tumors, with strong proof-of-concept data, phase III ready for sarcoma under SPA